Clinical Trials Browser

Terminated × Everolimus × Clear all

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT03839940 2025-01-29

MIST

Phase 3 Terminated

39 enrolled 18 charts

Neoplasms

NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00811590 2024-09-19

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Phase 2 Terminated

3 enrolled 4 charts

Neoplasms, Peutz-Jeghers Syndrome, Polyps

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT01345136 2024-02-13

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Phase 2 Terminated

Neuroma, Acoustic, Neurofibromatosis 2

NCT01215136 2023-11-24

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

36 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast Neoplasms

NCT02031536 2023-06-29

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Phase 2 Terminated

2 enrolled 8 charts

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02023905 2022-12-29

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Phase 2 Terminated

27 enrolled 15 charts

Astrocytoma, Oligodendroglioma

NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Phase 2 Terminated

3 enrolled 7 charts

Glioma, Brain Stem Neoplasms

NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1/2 Terminated

26 enrolled 11 charts

Carcinoma, Renal Cell

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02236572 2022-02-01

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2 Terminated

17 enrolled 11 charts

Breast Neoplasms

NCT00972335 2021-11-10

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase 2 Terminated

18 enrolled 5 charts

Meningioma

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 1/2 Terminated

23 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01125293 2021-04-23

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Terminated

46 enrolled 29 charts

Waldenstrom Macroglobulinemia

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Phase 3 Terminated

37 enrolled 16 charts

Breast Neoplasms

NCT01190241 2020-11-20

TSAP

Phase NA Terminated

Neoplasm Metastasis

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Phase 2 Terminated

17 enrolled 10 charts

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01627067 2020-06-19

Exemestane-RAD001-Metformin

Phase 2 Terminated

23 enrolled 7 charts

Breast Neoplasms

NCT01133678 2020-05-08

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Phase 2 Terminated

50 enrolled 9 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01111058 2020-04-07

Everolimus Versus Placebo in Head and Neck Cancer

Phase 2 Terminated

52 enrolled 13 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01057277 2020-02-17

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

Phase 1 Terminated

3 enrolled 6 charts

Head and Neck Neoplasms

NCT02254239 2019-12-12

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Terminated

Hodgkin Disease

NCT03578432 2019-12-02

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Phase EARLY_PHASE1 Terminated

Head and Neck Neoplasms, Mouth Neoplasms, Xerostomia

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell

NCT01648465 2019-09-03

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Phase 2 Terminated

Gastrointestinal

Digestive System Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03014297 2019-08-08

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Phase 1 Terminated

Neuroendocrine Tumors

NCT02504892 2019-03-22

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Phase 2 Terminated

3 enrolled 7 charts

Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Birt-Hogg-Dube Syndrome

NCT01198158 2019-03-06

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase 3 Terminated

77 enrolled 11 charts

Carcinoma, Renal Cell

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00526591 2018-12-06

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

Phase 2 Terminated

17 enrolled 10 charts

Prostatic Neoplasms

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Carcinoma, Renal Cell

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Neoplasms

NCT01009346 2018-07-17

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Phase 1/2 Terminated

9 enrolled 9 charts

Head and Neck Neoplasms

NCT02338570 2018-02-05

ORCHIDEE

Phase 4 Terminated

Carcinoma, Renal Cell

NCT02479490 2018-01-16

PREV

Phase 2 Terminated

Kidney Neoplasms

NCT00807755 2018-01-09

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Phase 1 Terminated

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01051791 2017-12-19

Phase II Study of RAD001 Head and Neck Cancer

Phase 2 Terminated

13 enrolled 5 charts

Squamous Cell Carcinoma of Head and Neck

NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms